
ScienceDaily
July 19, 20261 min read
A low-cost antidepressant may offer new hope for people struggling with long COVID fatigue. In a randomized clinical trial involving 399 adults, fluvoxamine significantly reduced fatigue and improved quality of life compared with a placebo, making it one of the first medications to show meaningful benefits for this disabling condition.
Read what's here, then head to the original whenever you're ready - never required.
Continue Reading on ScienceDaily
Advancing next-gen AI with materials science innovation
Hacker News July 21, 2026